OrbiMed, a leading global healthcare investment firm, announced it has raised $1.86 billion in commitments for OrbiMed Royalty and Credit Opportunities Fund V.
Consistent with its predecessors, Fund V will provide tailored investment solutions to growth-oriented healthcare companies, with a focus on non-dilutive credit and royalty-based financing. OrbiMed expects to partner with healthcare companies across many sectors, including biopharmaceuticals, medical devices, diagnostics and technology-enabled healthcare services.
Health Technology Insights: MAGENTIQ EYE Raises Series A Investment to Advance AI in Gastroenterology Care
“Equity markets have been challenging in recent years for biotech and life sciences companies,” said OrbiMed General Partner Matthew Rizzo. “Our flexible, non-dilutive capital solutions can help our portfolio companies to grow and thrive despite these volatile market conditions. The OrbiMed platform is uniquely positioned to fund healthcare innovation and growth on a global basis.”
Health Technology Insights: Cardinal Health Expands Equity Rx with $5Million Investment
Investors in this new fund include a broad range of medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices.
“Over 90% of Fund V’s committed capital is from existing, long-standing firm relationships,” said OrbiMed Managing Partner Carter Neild. “We are grateful for this support, and will endeavor to deliver exceptional results to our partners.”
Health Technology Insights: COTA and LCP Partner to Advance US RWD for Global HTA Decision Making
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- PR Newswire
